Global epigenetic profiling in bladder cancer

Epigenomics

Volumn 3, Issue 1, 2011, Pages 35-45

  Dudziec, Ewa ^a   Goepel, John R ^b   Catto, James W F ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

bladder; DNA methylation; epigenetic regulation; histone modifications; miRNAs; urothelial cell carcinoma

Indexed keywords

3 DEAZANEPLANOCIN A; 4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MICRORNA; TRICHOSTATIN A; UNTRANSLATED RNA; UVOMORULIN; VALPROIC ACID; VORINOSTAT;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CATALYSIS; CELL CYCLE REGULATION; DEMETHYLATION; DNA HISTONE INTERACTION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SILENCING; GENETIC MODEL; GENETIC STABILITY; HIGH RISK PATIENT; HISTONE MODIFICATION; HUMAN; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA; UPREGULATION;

CARCINOMA; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; RNA, UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 79951878191     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.10.71     Document Type: Review

References (104)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Avritscher EB, Cooksley CD, Grossman HB et al.: Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 68(3), 549-553 (2006). (Pubitemid 44436509)
3. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA: The economic consequences of prostate and bladder cancer in the UK. BJU Int. 95(1), 59-63 (2005). (Pubitemid 350020870)
4. PJ Goebell, Knowles MA: Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28(4), 409-428 (2010).
5. Catto JW, Rosario DJ: The road to cystectomy: who, when and why? EAU update series. Eur. Urol. 3(4), 171-179 (2005).
6. Catto JW, Yates DR, Rehman I et al.: Behavior of urothelial carcinoma with respect to anatomical location. J. Urol. 177(5), 1715-1720 (2007). (Pubitemid 46560675)
7. Stein JP, Lieskovsky G, Cote R et al.: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001). (Pubitemid 32120143)
8. Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27(3), 361-373 (2006). (Pubitemid 43372866)
9. Dhawan D, Hamdy FC, Rehman I et al.: Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J. Pathol. 209(3), 336-343 (2006). (Pubitemid 43997742)
10. Dyrskjot L, Kruhoffer M, Thykjaer T et al.: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64(11), 4040-4048 (2004). (Pubitemid 38697320)
11. van Oers JM, Zwarthoff EC, Rehman I et al.: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumors. Eur. Urol. 55(3), 650-657 (2009).
12. Jebar AH, Hurst CD, Tomlinson DC et al.: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24(33), 5218-5225 (2005). (Pubitemid 41192438)
13. Zhang ZT, Pak J, Huang HY et al.: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20(16), 1973-1980 (2001). (Pubitemid 32458029)
14. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 59(14), 3512-3517 (1999). (Pubitemid 29334516)
15. Spruck CH, Ohneseit PF, Gonzalez- Zulueta M et al.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54(3), 784-788 (1994). (Pubitemid 24068337)
16. Catto JW, Miah S, Owen HC et al.: Distinct miRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 69(21), 8472-8481 (2009).
17. Yates DR, Rehman I, Abbod MF et al.: Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13(7), 2046-2053 (2007). (Pubitemid 46649871)
18. Dyrskjot L, Ostenfeld MS, Bramsen JB et al.: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 69(11), 4851-4860 (2009).
19. Serizawa RR, Ralfkiaer U, Steven K et al.: Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int J. Cancer doi: 10.1002/ijc.25651 (2010) (Epub ahead of print).
20. Weisenberger DJ, Siegmund KD, Campan M et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38(7), 787-793 (2006). (Pubitemid 43980599)
21. Ordway JM, Williams K, Curran T: Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1. Oncogene 23(21), 3737-3748 (2004). (Pubitemid 38725687)
22. Watt F, Molloy PL: Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 2(9), 1136-1143 (1988).
23. Nan X, Campoy FJ, Bird A: MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88(4), 471-481 (1997). (Pubitemid 27154412)
24. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300(5618), 455 (2003). (Pubitemid 36444319)
25. Gaudet F, Hodgson JG, Eden A et al.: Induction of tumors in mice by genomic hypomethylation. Science 300(5618), 489-492 (2003). (Pubitemid 36444330)
26. Estecio MR, Gharibyan V, Shen L et al.: LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS ONE 2(5), e399 (2007).
27. Prusty BK, zur Hausen H, Schmidt R, Kimmel R, de Villiers EM: Transcription of HERV-E and HERV-E-related sequences in malignant and non-malignant human haematopoietic cells. Virology 382(1), 37-45 (2008).
28. Lamprecht B, Walter K, Kreher S et al.: Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat. Med. 16(5), 571-579 (2010).
29. Wolff EM, Byun HM, Han HF et al.: Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 6(4), e1000917 (2010).
30. Buscher K, Hahn S, Hofmann M et al.: Expression of the human endogenous retrovirus-K transmembrane envelope, Rec and Np9 proteins in melanomas and melanoma cell lines. Melanoma Res. 16(3), 223-234 (2006). (Pubitemid 44085096)
31. Ishida T, Obata Y, Ohara N et al.: Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun. 8, 15 (2008).
32. Wang-Johanning F, Liu J, Rycaj K et al.: Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer. Int. J. Cancer. 120(1), 81-90 (2007). (Pubitemid 44901921)
33. Dudziec E, Miah S, Choudhry H et al.: Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. Clin. Cancer Res. (2010) (Epub ahead of print).
34. Marsit CJ, Houseman EA, Christensen BC et al.: Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE 5(8), e12334 (2010).
35. Wolff EM, Chihara Y, Pan F et al.: Unique DNA methylation patterns distinguish superficial and invasive bladder cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70(20), 8169-8178 (2010).
36. Catto JW, Hartmann A, Stoehr R et al.: Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J. Urol. 175(6), 2323-2330 (2006). (Pubitemid 43668524)
37. Catto JW, Azzouzi AR, Rehman I et al.: Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23(13), 2903-2910 (2005). (Pubitemid 46224108)
38. Cebrian V, Alvarez M, Aleman A et al.: Discovery of myopodin methylation in bladder cancer. J. Pathol. 216(1), 111-119 (2008).
39. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol Chem. 275(4), 2727-2732 (2000). (Pubitemid 30082043)
40. Byun HM, Wong HL, Birnstein EA et al.: Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 67(22), 10753-10758 (2007). (Pubitemid 350145902)
41. Wilhelm CS, Kelsey KT, Butler R et al.: Implications of LINE1 methylation for bladder cancer risk in women. Clin. Cancer Res. 16(5), 1682-1689 (2010).
42. Choi SH, Worswick S, Byun HM et al.: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J. Cancer. 125(3), 723-729 (2009).
43. Moore LE, Pfeiffer RM, Poscablo C et al.: Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol. 9(4), 359-366 (2008).
44. Kouzarides T: Chromatin modifications and their function. Cell. 128(4), 693-705 (2007). (Pubitemid 46273577)
45. Nguyen CT, Weisenberger DJ, Velicescu M et al.: Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2́-deoxycytidine. Cancer Res. 62(22), 6456-6461 (2002). (Pubitemid 35364106)
46. Wiencke JK, Zheng S, Morrison Z, Yeh RF: Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 27(17), 2412-2421 (2008). (Pubitemid 351521100)
47. Vakoc CR, Mandat SA, Olenchock BA, Blobel GA: Histone H3 lysine 9 methylation and HP1g are associated with transcription elongation through mammalian chromatin. Mol. Cell 19(3), 381-391 (2005). (Pubitemid 41074893)
48. Squazzo SL, O'Geen H, Komashko VM et al.: Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 16(7), 890-900 (2006). (Pubitemid 43992913)
49. Kondo Y, Shen L, Cheng AS et al.: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 40(6), 741-750 (2008). (Pubitemid 351748874)
50. Weikert S, Christoph F, Kollermann J et al.: Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int. J. Mol. Med. 16(2), 349-353 (2005).
51. Varambally S, Dhanasekaran SM, Zhou M et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419(6907), 624-629 (2002).
52. Kleer CG, Cao Q, Varambally S et al.: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100(20), 11606-11611 (2003). (Pubitemid 37205983)
53. Cao Q, Yu J, Dhanasekaran SM et al.: Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27(58), 7274-7284 (2008).
54. Ou JN, Torrisani J, Unterberger A et al.: Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem. Pharmacol. 73(9), 1297-1307 (2007). (Pubitemid 46452588)
55. Sachs MD, Ramamurthy M, Poel H et al.: Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther. 11(7), 477-486 (2004). (Pubitemid 38902674)
56. Selbach M, Schwanhausser B, Thierfelder N et al.: Widespread changes in protein synthesis induced by microRNAs. Nature 455(7209), 58-63 (2008).
57. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10(10), 704-714 (2009).
58. Gottardo F, Liu CG, Ferracin M et al.: Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 25(5), 387-392 (2007). (Pubitemid 47362758)
59. Valadi H, Ekstrom K, Bossios A et al.: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9(6), 654-659 (2007). (Pubitemid 47214727)
60. Hanke M, Hoefig K, Merz H et al.: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28(6), 655-661 (2010).
61. Saito Y, Liang G, Egger G et al.: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9(6), 435-443 (2006). (Pubitemid 43832188)
62. Saito Y, Friedman JM, Chihara Y et al.: Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem. Biophys. Res. Commun. 379(3), 726-731 (2009).
63. Wiklund ED, Bramsen JB, Hulf T et al.: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int. J. Cancer (2010) (Epub ahead of print).
64. Fabbri M, Garzon R, Cimmino A et al.: MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B Proc. Natl Acad. Sci. USA 104(40), 15805-15810 (2007). (Pubitemid 350035380)
65. Friedman JM, Liang G, Liu CC et al.: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 69(6), 2623-2629 (2009).
66. Brunk BP, Goldhamer DJ, Emerson CC Jr: Regulated demethylation of the myoD distal enhancer during skeletal myogenesis. Dev. Biol. 177(2), 490-503 (1996). (Pubitemid 26275900)
67. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al.: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223-232 (2009).
68. Gore SD, Baylin S, Sugar E et al.: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66(12), 6361-6369 (2006).
69. Kim MS, Blake M, Baek JH et al.: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 63(21), 7291-7300 (2003). (Pubitemid 37413470)
70. Hauswald S, Duque-Afonso J, Wagner MM et al.: Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 15(11), 3705-3715 (2009).
71. Cheng JC, Weisenberger DJ, Gonzales FA et al.: Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell Biol. 24(3), 1270-1278 (2004). (Pubitemid 38112188)
72. Christoph F, Kempkensteffen C, Weikert S et al.: Methylation of tumor suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br. J. Cancer. 95(12), 1701-1707 (2006). (Pubitemid 44950797)
73. Aleman A, Cebrian V, Alvarez M et al.: Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res. 14(24), 8236-8243 (2008).
74. Huang Y, Stewart TM, Wu Y et al.: Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 15(23), 7217-7228 (2009).
75. Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR: Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 29(4), 576-588 (2010).
76. Tan J, Yang X, Zhuang L et al.: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007). (Pubitemid 46686474)
77. Gupta R, Nagarajan A, Wajapeyee N: Advances in genome-wide DNA methylation analysis. Biotechniques 49(4), iii-xi (2010).
78. Pomraning KR, Smith KM, Freitag M: Genome-wide high throughput analysis of DNA methylation in eukaryotes. Methods 47(3), 142-150 (2009).
79. Park PJ: ChIP-seq: advantages and challenges of a maturing technology. Nat. Rev. Genet. 10(10), 669-680 (2009).
80. Irizarry RA, Ladd-Acosta C, Wen B et al.: The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
81. Lister R, Pelizzola M, Dowen RH et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
82. Kim WJ, Kim EJ, Jeong P et al.: RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 65(20), 9347-9354 (2005). (Pubitemid 41508002)
83. Dominguez G, Carballido J, Silva J et al.: p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 8(4), 980-985 (2002). (Pubitemid 35177345)
84. Chan MW, Chan LW, Tang NL et al.: Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8(2), 464-470 (2002). (Pubitemid 34193966)
85. Hoque MO, Begum S, Topaloglu O et al.: Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006). (Pubitemid 44288164)
86. Friedrich MG, Chandrasoma S, Siegmund KD et al.: Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer. 41(17), 2769-2778 (2005). (Pubitemid 41607571)
87. Ellinger J, El Kassem N, Heukamp LC et al.: Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179(1), 346-352 (2008). (Pubitemid 350216721)
88. Maruyama R, Toyooka S, Toyooka KO et al.: Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61(24), 8659-8663 (2001). (Pubitemid 34013873)
89. Abbosh PH, Wang M, Eble JN et al.: Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. Mod. Pathol. 21(3), 355-362 (2008). (Pubitemid 351304290)
90. Yang J, Xu Z, Li J et al.: XPC epigenetic silence coupled with p53 alteration has a significant impact on bladder cancer outcome. J. Urol. 184(1), 336-343 (2010).
91. Friedrich MG, Weisenberger DJ, Cheng JC et al.: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10(22), 7457-7465 (2004). (Pubitemid 39557507)
92. Marsit CJ, Houseman EA, Schned AR, Karagas MR, Kelsey KT: Promoter hypermethylation is associated with current smoking, age, gender and survival in bladder cancer. Carcinogenesis 28(8), 1745-1751 (2007). (Pubitemid 47289037)
93. Sathyanarayana UG, Maruyama R, Padar A et al.: Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 64(4), 1425-1430 (2004). (Pubitemid 38235612)
94. Aleman A, Adrien L, Lopez-Serra L et al.: Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer 98(2), 466-473 (2008). (Pubitemid 351161244)
95. Tada Y, Wada M, Taguchi K et al.: The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 62(14), 4048-4053 (2002). (Pubitemid 34791073)
96. Chiyomaru T, Enokida H, Kawakami K et al.: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol. Oncol. (2010) (Epub ahead of print).
97. Cao Y, Yu SL, Wang Y et al.: MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumor Biol. 32(1), 179-188 (2010).
98. Ichimi T, Enokida H, Okuno Y et al.: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J. Cancer. 125(2), 345-352 (2009).
99. Lodygin D, Tarasov V, Epanchintsev A et al.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7(16), 2591-2600 (2008).
100. Huang L, Luo J, Cai Q et al.: MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int. J. Cancer doi: 10.1002/ ijc.25509 (2010) (Epub ahead of print).
101. Chiyomaru T, Enokida H, Tatarano S et al.: miR-145 and miR-133a function as tumor suppressors and directly regulate FSCN1 expression in bladder cancer. Br. J. Cancer 102(5), 883-891 (2010).
102. Ostenfeld MS, Bramsen JB, Lamy P et al.: miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29(7), 1073-1084 (2010).
103. Adam L, Zhong M, Choi W et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin. Cancer Res. 15(16), 5060-5072 (2009).
104. Lu Q, Lu C, Zhou GP et al.: MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol. Oncol. (6), 635-641 (2009).